Figure 1.

Knockdown of Twist1 enhances NSCLC cell sensitivity to cisplatin. (a) A549 and H1299 cells were treated with the indicated concentrations of cisplatin for 24 h. Cell viability was measured with the MTT assay. The viability of control cells was set at 100%, and survival relative to the control presented. (b) A549 and H1299 cells were transfected with two different Twist1 or control siRNAs for 30 h. Twist1 mRNA levels were measured using RT-PCR analysis. (c and d) A549 and H1299 cells were transfected with siCTL or siTwist1 for 20 h, followed by 8 (A549 cells) or 6 μM (H1299 cells) cisplatin for 24 h. Cell viability was measured with the MTT assay (c) and protein levels determined using western blot analysis (d). Data shown are representative of three independent experiments. All graphs are shown as the mean of each group and error bars represent S.D. **P<0.01 versus the siCTL/cisplatin-treated group or siTwist1-treated group